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Abstract
Purpose Among a cohort of postmenopausal breast cancer survivors, we aimed to compare the risk of dementia associated with
aromatase inhibitor (AI) therapy versus tamoxifen.
Methods Using UK primary care electronic health records, we identified 14,214 postmenopausal breast cancer survivors (aged ≥
54 years) with a first AI or tamoxifen prescription between January 2002 and December 2015 and no previous dementia
diagnosis. Women were followed-up to identify incident cases of dementia. Cox regression was used to calculate hazard ratios
(HRs) with 95% confidence intervals (CIs) to quantify the association between AI exposure (vs. tamoxifen) and dementia,
adjusted for confounders.
Results A total of 368 incident dementia cases was identified over 57,102 person-years of follow-up. The crude incidence rate of
dementia was 7.46 per 1000 person-years (95%CI 6.43–8.65) among women starting endocrine treatment on an AI, and 6.32 per
1000 person-years (95% CI 5.34–7.47) among women starting on tamoxifen. After accounting for age differences and assessing
other potential confounders, there was no evidence of a difference in dementia risk between exposure groups (HR for AI vs
tamoxifen 1.04, 95% CI 0.83–1.03). There was no evidence of effect modification by age.
Conclusion There was no evidence for a difference in dementia risk between AI and tamoxifen users among postmenopausal
breast cancer survivors.
Implications for Cancer Survivors Our findings suggest that there is no reason for concern about a difference in dementia risk with
AI vs. tamoxifen, which is relevant to postmenopausal breast cancer patients recommended these treatments.
Keywords Breast cancer . Dementia . Aromatase inhibitors . Clinical epidemiology
Introduction
Adjuvant endocrine therapy remains the mainstay of treatment
for postmenopausal women with oestrogen-receptor positive
breast cancer. Aromatase inhibitors (AIs)—anastrozole,
exemestane, and letrozole—have become the preferred
treatment in this patient population [1, 2], being superior to
tamoxifen in reducing breast cancer recurrence rates and 10-
year breast cancer mortality rates [3, 4]. Already widely used
drugs, AIs will likely grow in use as the number of breast
cancer survivors increases [5], highlighting the importance
of evaluating their safety.
Over recent decades, there has been much interest in
whether adjuvant endocrine therapy is adversely associated
with cognitive functioning in breast cancer survivors—a com-
monly reported side effect in these patients [6]. Substantial
biological evidence supports a role for oestrogen in maintain-
ing cognitive functioning [7], suggesting that the anti-
oestrogen effects of endocrine therapy may have detrimental
cognitive consequences. Sub-studies of randomized con-
trolled trials (RCTs) have shown that in breast cancer patients,
endocrine therapy, either as a group or tamoxifen alone, re-
duces performance on specific cognitive domains compared
with non-cancer controls [8, 9]. Findings from observational
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studies on this topic have been mixed, with several studies
having small sample sizes, a cross-sectional design, or with
limited follow-up [7, 10–14].
As the majority of women with oestrogen-receptor positive
breast cancer will actually receive treatment with either an AI
or tamoxifen, an important question is whether there is a dif-
ferent effect on cognition function between these two treat-
ments. Owing to their different mechanisms of action, circu-
lating oestradiol levels are substantially lower following treat-
ment with AIs than with tamoxifen [15], and could therefore
potentially have a greater detrimental effect on cognition.
Results from RCT sub-studies [8, 16], however, do not sup-
port this hypothesis, with patients on AI performing signifi-
cantly better on specific cognitive domains than those on ta-
moxifen. Observational data directly comparing AIs and ta-
moxifen in this context are limited, with a small meta-analysis
of data from six cross-sectional studies reporting no differ-
ences between treatments on cognitive performance [11].
There have been no population-based studies directly compar-
ing the effect of AIs versus tamoxifen on the risk of dementia.
Therefore, using routinely collected primary care data from
the United Kingdom (UK), we performed a cohort study that
aimed to compare the risk of incident dementia among post-
menopausal breast cancer survivors prescribed AI therapy
with those prescribed tamoxifen.
Methods
Data source
We used data from the Clinical Practice Research Datalink
General Practice Online Data (CPRD GOLD) primary care
database of anonymised electronic health records (EHRs),
which covers approximately 7% of the UK population, and
to which 674 general practices across the UK have contributed
patient data [17, 18]. The database enables long-term follow-
up of population-based cohorts for pharmacoepidemiological
research. Information is recorded by general practitioners and
other primary care health professionals as part of routine pa-
tient care under the UK’s National Health Service, which pro-
vides universal free healthcare. The data recorded includes
patient demographics, clinical symptoms, diagnoses, and re-
ferrals to secondary care, which are entered using Read codes
(coded clinical terminology used for recording in the UK) [19]
as well as all prescriptions issued. Information from secondary
care sent by emails and letters is also recorded. Diagnoses in
CPRD GOLD have generally been found to have high valid-
ity, [17] including for dementia diagnoses, which have an 83–
84% positive predictive value (PPV) [20, 21]. In the UK,
dementia is largely managed in primary care, making CPRD
GOLD an appropriate setting for capturing dementia cases.
Through linkage to UK cancer registrations, over 90% of
breast cancer diagnoses in CPRD GOLD have been validated,
and over 90% percent of breast cancer registrations are captured
in CPRDGOLD [22]. The database is broadly representative of
the UK demographic in terms of age, sex, and ethnicity [23].
The study protocol was approved by the Independent Scientific
Advisory Committee for Medicines and Healthcare products
Regulatory Agency (reference 17–122), and ethical approval
for this study was obtained from The LSHTM Research
Ethics Committee (MSc Ethics Ref: 13465).
Study population
Identification of the study population is depicted in the Fig. 1.
We included all women in CPRD GOLD with a permanent
registration status, aged at least 54 years (median age of nat-
ural menopause in European women) [24], and with a first
prescription for an AI (anastrozole, exemestane, or letrozole)
or tamoxifen following a first recorded diagnosis of breast
cancer between 1 January 2002 and 31 December 2015.
Although AIs were not advocated by the National Institute
for Health and Care Excellence until 2006 [25], preliminary
analysis indicated widespread use of these drugs in preceding
years. Although oestrogen-receptor positive status of breast
cancer is not available in the database, women were assumed
to have oestrogen-receptor positive disease because this is the
indication for endocrine therapy.Womenwere also required to
have at least 12-month follow-up in the database before their
first breast cancer diagnosis and to be still alive and registered
with the general practice 1-year post-diagnosis. The index
date was 1 year following breast cancer diagnosis or the date
of first prescription for endocrine therapy (AI/tamoxifen) if
this came later; the rationale was to minimize the possibility
that any immediate effects on these outcomes would have
been due to initial chemotherapy/radiotherapy treatment as
well as tominimize the possibility of including prevalent cases
of dementia. Patients whose index date occurred after the end
of the study periodwere excluded.Womenwere also excluded
if they had any of the following before the index date: a Read
code for dementia (Appendix Table 1); a dementia-specific
medication prescription (Appendix Table 2); or a recorded
diagnosis of a different cancer.
Exposure to AI/tamoxifen therapy
In the UK, the recommended duration of use for AIs during
the period of this study was 5 years or 3 years as part of a
sequential regimen following 2-year tamoxifen treatment [25].
Endocrine therapy was categorized according to initial treat-
ment prescribed, either AI or tamoxifen. If a woman switched
from tamoxifen to an AI, they moved into a separate exposure
category “AI preceded by tamoxifen” on the date of their first
AI prescription, while women who switched from an AI to
tamoxifen moved into an exposure category “tamoxifen
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preceded by AI” on the date of their first tamoxifen prescrip-
tion. Women were still able to contribute person-time to ex-
posure categories if they had a gap in treatment and later
restarted on either the same medication or switched treatment.
A stop in treatment was defined as no prescription within
30 days after the end of the previous prescription.
Follow-up and dementia outcomes
The primary outcome of interest was any type of incident
dementia, defined as a first record of a prescription for a
dementia-specific medication (Appendix Table 2) or Read
code indicative of incident dementia (Appendix Table 3).
Where possible, based on specific Read codes (Appendix
Table 4), dementia cases were classed according to sub-
type—Alzheimer’s disease, vascular dementia, dementia with
Lewy bodies, or mixed dementia—otherwise they were
classed as unknown type. Follow-up began at the index date
and ended at the earliest of incident dementia as defined
above, death, transfer out of the practice, or end of the study
period (31 December 2015).
Covariates
Variables evaluated as potential confounders included age at
the start of endocrine therapy (< 75 years and ≥ 75 years),
practice level index of multiple deprivation (IMD)—a
measure of socioeconomic deprivation (five quartiles with 1
being the least deprived and 5 being the most deprived) [23],
smoking (never, current, ex-smoker, or unknown), body mass
index (BMI in kg/m2; < 18, 18 to 25, 25 to < 30, ≥ 30, or
unknown), alcohol consumption (never, current [light, moder-
ate, heavy, or unknown quantity], ex-drinker, and unknown),
diabetes (type I or II), hypertension, cardiovascular disease
(CVD), cerebrovascular disease, hyperlipidaemia, depression,
use of hormone replacement therapy (HRT), and time since the
index date (time-updated; < 1 year, 1 to < 2 years; 2 to < 5 years,
5 to < 10 years, and ≥ 10 years). For lifestyle variables, we used
the most recently recorded status/value before the index date.
Statistical analysis
Baseline variables were described according to initial endo-
crine therapy prescribed, using frequency counts and percent-
ages for categorical variables and means with standard devia-
tion (SD) for continuous variables. Mantel-Haenszel stratifi-
cation was used to calculate the crude incidence rate ratio with
95% confidence interval (95% CI) for incident dementia com-
paring use of AIs with tamoxifen (reference group) as first
endocrine therapy. Cox regression (using age as the timescale)
was used with AI exposure as a time-updated variable to quan-
tify the association between use of AIs (vs. tamoxifen) and
incident dementia, adjusted for confounders. Hazard ratios
(HRs) with 95% CIs were calculated for any type of dementia
Women in CPRD GOLD with a registraon status of 
permanent or died and with a prescripon for an AI or 
tamoxifen following a first diagnosis of breast cancer 
diagnosis between 1 January 2002 and 
31 December 2015
N=30 216
Exclusions 
Aged <54 years at breast cancer 
diagnosis, n=467
Prescripons for an AI or tamoxifen 
prior breast cancer diagnosis, n=1429
Breast cancer diagnosis <1 year aer 
start of follow-up in CPRD GOLD, n=2
Exclusions
Transferred out of pracce, died, or 
pracce stopped contribung to
CPRD GOLD before the index date, 
n=8608
Another cancer before the index 
date, n=3691
Stopped or switched AI/tamoxifen 
before the index date, n=1510
Demena Read code/prescripon for 
dementia medicaon before the 
index date, n=295
Final study populaon
N=14 214
Women aged ≥54 years with a first prescripon for an AI 
or tamoxifen following breast cancer diagnosis and with 
≥1 year aer start of follow-up in CPRD GOLD
N=28 318
Index date set as 1 year aer breast cancer diagnosis or 
date of first AI/tamoxifen prescripon if this was later
Fig. 1 Identification of the
postmenopausal breast cancer
study population. AI, aromatase
inhibitor; Clinical Practice
Research Datalink (CPRD)
GOLD
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as the primary outcome, and for Alzheimer’s disease and vas-
cular dementia as secondary outcomes (because of their dif-
ferent aetiologies, it is possible that an association between
AIs and dementia could vary between subtypes). The main
comparison of interest was between person-time on an AI as
first endocrine therapy (prior to any switch) and person-time
on tamoxifen as first endocrine therapy (prior to any switch).
In the Cox regression modelling, each potential confounder
was added to the attained-age adjusted model one at a time,
i.e. a series of 2-variable models, with a change in the HR of
10% or more compared with the age-only model deemed to
provide evidence of confounding by the added variable. For
variables with missing data (smoking, alcohol consumption,
and BMI), potential confounding for each was explored using
a complete case approach (excluding patients with missing
data on that particular variable). A sensitivity analyses was
performed, restricting to dementia cases identified on the basis
of a Read code (i.e. those with only a dementia medication
Table 1 Baseline characteristics of postmenopausal 1-year breast cancer survivors prescribed AI/tamoxifen, overall, and by initial treatment
Characteristic Patients starting with
an AI (N = 8018)
Patients starting with
tamoxifen (N = 6196)
Overall study
population (N = 14,214)
Age (years)
55–64 2695 (33.6) 2568 (41.5) 5263 (37.0)
65–74 2629 (32.8) 2131 (34.4) 4760 (33.5)
≥ 75 2694 (33.6) 1497 (24.2) 4191 (29.5)
Mean (SD) 70.9 (9.9) 68.6 (9.4) 69.9 (9.7)
Median (IQR) 69.2 (62.9–78.6) 67.2 (61.2–74.6) 68.3 (62.1–77.0)
Calendar year
2003–2006 942 (11.8) 2886 (46.6) 3828 (26.9)
2007–2009 2049 (25.6) 1606 (25.9) 3655 (25.7)
2010–2012 2634 (32.9) 967 (15.6) 3601 (25.3)
2013–2015 2393 (29.9) 737 (11.9) 3130 (22.0)
Practice-level IMD
1 (least deprived) 1768 (22.1) 1216 (19.6) 2984 (21.0)
2 1620 (20.2) 1305 (21.1) 2925 (20.6)
3 1629 (20.3) 1422 (23.0) 3051 (21.5)
4 1619 (20.2) 1210 (19.5) 2829 (19.9)
5 (most deprived) 1382 (17.2) 1043 (16.8) 2425 (17.1)
BMI (kg/m2)*
Underweight (< 18) 95 (1.3) 73 (1.2) 168 (1.3)
Healthy weight (18 to < 25) 2417 (31.8) 2190 (37.3) 4607 (34.2)
Overweight (25 to < 30) 2718 (35.8) 2068 (35.2) 4786(35.5)
Obese (≥ 30) 2366 (31.2) 1540 (26.2) 3906 (29.0)
Unknown 422 (5.3) 325 (5.2) 747 (5.3)
Mean (SD) 28.0 (5.8) 27.2 (5.4) 27.7 (5.6)
Median (IQR) 27.1 (24.0–31.2) 26.4 (23.4–30.1) 26.8 (23.7–30.8)
Smoking*
Never 3099 (38.8) 2466 (40.0) 5565 (39.3)
Current 834 (10.4) 874 (14.2) 1708 (12.1)
Former 4065 (50.8) 2833 (45.9) 6898 (48.7)
Unknown 20 (0.3) 23 (0.4) 43 (0.3)
Alcohol consumption*
Never 1016 (13.5) 833 (14.3) 1849 (13.9)
Current drinker
Low 4485 (59.7) 3649 (62.7) 8134 (61.0)
Medium 331 (4.4) 251 (4.3) 582 (4.4)
Heavy 98 (1.3) 82 (1.4) 180 (1.4)
Unknown 531 (7.1) 368 (6.3) 899 (6.7)
Ex-drinker 1055 (14.0) 640 (11.0) 1695 (12.7)
Unknown 502 (6.3) 373 (6.0) 875 (6.2)
Comorbidity/comedication*
Hypertension 4019 (50.1) 2621 (42.3) 6640 (46.7)
Diabetes 998 (12.5) 557 (9.0) 1555 (10.4)
Hyperlipidaemia 1662 (20.7) 958 (15.5) 2620 (18.4)
CVD 1837 (22.9) 866 (14.0) 2703 (19.0)
CeVD 382 (4.8) 129 (2.1) 511 (3.6)
Depression 2473 (30.8) 1700 (27.4) 4173 (29.4)
HRT 2767 (34.5) 2340 (37.8) 5107 (35.9)
* Ever before the index date (for lifestyle variables, the most recent value/status was used). AI aromatase inhibitor, BMI body mass index, CeVD
cerebrovascular disease, CVD cardiovascular disease, HRT hormone replacement therapy, IMD index of multiple deprivation
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Table 2 Incidence rates and adjusted HRs (with 95% CIs) for the association between AI exposure (and other explanatory variables) and incident
dementia among postmenopausal 1-year breast cancer survivors prescribed AI/tamoxifen
Explanatory variable Incident dementia
cases, n
N = 368
Total person-years
(1000s)
Crude incidence rate
of dementia per 1000
person-years (95% CI)
Age-adjusted HRa p value*
AI exposure
Tamoxifen as first endocrine therapy 136 21.54 6.32 (5.34–7.47) 1.0 (reference)
AI as first endocrine therapy 175 23.46 7.46 (6.43–8.65) 1.04 (0.83–1.30)
AI with prior tamoxifen use 43 10.48 4.10 (3.04–5.53) 0.73 (0.52–1.04)
Tamoxifen with prior AI use 14 1.62 8.63 (5.11–14.57) 1.11 (0.64–1.93) 0.186
Age at index date (years)
55–64 27 24.27 1.11 (0.76–1.62) 1.0 (reference)
65–74 93 19.74 4.71 (3.84–5.77) 0.88 (0.42–1.67)
≥ 75 248 13.08 18.96 (16.74–21.47) 0.87 (0.41–1.84) 0.9264
Calendar year
2003–2006 174 23.93 7.27 (6.27–8.44) 1.0 (reference)
2007–2009 88 17.85 4.93 (4.00–6.08) 0.75 (0.58–0.96)
2010–2012 87 11.34 7.67 (6.22–9.46) 1.19 (0.92–1.54)
2013–2015 19 3.98 4.77 (3.04–7.48) 0.79 (0.49–1.27) 0.0136
IMD (practice level)
1 (least deprived) 70 12.29 5.70 (4.51–7.20) 1.0 (reference)
2 79 11.72 6.74(5.41–8.40) 1.16 (0.84–1.60)
3 72 12.23 5.89 (4.67–7.42) 0.90 (0.65–1.25)
4 69 11.16 6.18 (4.88–7.83) 1.02 (0.73–1.42)
5 (most deprived) 78 9.70 8.04 (6.44–10.04) 1.32 (0.96–1.83) 0.158
BMI (kg/m2)
Underweight (< 18) 10 0.51 19.80 (10.65–36.80) 1.53 (0.80–2.92)
Healthy weight (18 to < 25) 142 19.01 7.47 (6.34–8.81) 1.0 (reference)
Overweight (25 to < 30) 118 19.86 5.94 (4.96–7.12) 0.76 (0.60–0.98)
Obese (≥ 30) 74 15.49 4.78 (3.80–6.00) 0.76 (0.57–1.01) 0.035
Smoking
Never 148 22.87 6.47 (5.51–7.60) 1.0 (reference)
Current 40 7.73 5.18 (3.80–7.06) 1.14 (0.80–1.62)
Former 178 26.45 6.73 (5.81–7.79) 1.14 (0.92–1.42) 0.467
Alcohol consumption
Never 71 7.75 9.16 (7.26–11.56) 1.0 (reference)
Current low 178 33.96 5.24 (4.53–6.07) 0.81 (0.62–1.07)
Current medium 10 2.37 4.21 (2.27–7.83) 0.92 (0.47–1.79)
Current high 4 0.61 6.58 (2.47–17.54) 1.29 (0.47–3.53)
Unknown 28 3.46 8.10(5.59–11.73) 1.13 (0.73–1.75)
Ex-drinker 54 6.03 8.96 (6.86–11.69) 1.01 (0.71–1.44) 0.391
Diabetes
No 320 51.77 6.18 (5.54–6.90) 1.0 (reference)
Yes 48 5.33 9.01 (6.79–11.95) 1.09 (0.81–1.48) 0.5661
Hypertension
No 156 31.77 4.91 (4.20–5.75) 1.0 (reference)
Yes 212 25.34 8.37 (7.31–9.57) 0.96 (0.78–1.19) 0.705
CeVD
No 339 55.66 6.09 (5.48–6.77) 1.0 (reference)
Yes 29 1.44 20.16 (14.01–29.01) 1.57 (1.07–2.30) 0.0301
CVD
No 254 47.50 5.35 (4.73–6.05) 1.0 (reference)
Yes 114 9.60 11.87 (9.88–14.27) 1.22 (0.98–1.53) 0.0839
Hyperlipidaemia
No 288 47.42 6.07 (5.41–6.82) 1.0 (reference)
Yes 80 9.69 8.26 (6.63–10.28) 1.16 (0.90–1.49) 0.2546
Depression
No 262 41.33 6.34 (5.62–7.15) 1.0 (reference)
Yes 106 15.77 6.72 (5.56–8.13) 1.26 (1.01–1.58) 0.0472
HRT
No 294 35.38 8.31 (7.41–9.32) 1.0 (reference)
Yes 74 21.72 3.41 (2.71–4.28) 0.98 (0.75–1.29) 0.900
a Significance testing was performed using the likelihood ratio test
AI aromatase inhibitor, BMI bodymass index,CI confidence interval,CVD cardiovascular disease,CeVD cerebrovascular disease,HR hazard ratio,HRT
hormone replacement therapy, IMD index of multiple deprivation, RR rate ratio
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prescription during follow-up were deemed non-cases).
Potential effect modification by age and previous use of
HRTwas investigated. Stata 14 (Stata Corp, Texas) was used
for all analyses.
Table 3 HRs (95% CI) for the
association between AI (vs.
tamoxifen) and incident dementia
among postmenopausal 1-year
breast cancer survivors prescribed
AI/tamoxifen, adjusted for
potential confounders
HR for dementia (95% CI)*
Adjusted for attained age only (final model) 1.04 (0.83–1.03)
Adjusted for attained age plus
Age at index date 1.05 (0.84–1.32)
Calendar year 1.10 (0.86–1.41)
IMD (practice-level) 1.04 (0.83–1.31)
BMI† 1.07 (0.85–1.36)
Smoking† 1.04 (0.83–1.30)
Alcohol consumption† 1.05 (0.83–1.33)
CVD‡ 1.02 (0.82–1.28)
CeVD‡ 1.02 (0.81–1.28)
Hypertension‡ 1.05 (0.84–1.31)
Hyperlipidaemia‡ 1.03 (0.82–1.29)
Diabetes‡ 1.04 (0.83–1.30)
Depression‡ 1.03 (0.83–1.29)
HRT use‡ 1.04 (0.83–1.30)
Time since index date 1.08 (0.86–1.93)
All the above variables 1.08 (0.84–1.38)
* From Cox regression with age as timescale; AI vs. tamoxifen exposure. †Using the nearest value/status before
the index date. ‡Recorded any time before the index date
AI aromatase inhibitor, BMI body mass index, CeVD cerebrovascular disease, CVD cardiovascular disease, CI
confidence interval, HR hazard ratio, HRT hormone replacement therapy, IMD Index of Multiple Deprivation
Table 4 HRs (95% CI) for the association between AI exposure and incidence dementia among postmenopausal 1-year breast cancer survivors
prescribed AI/tamoxifen, by age at first endocrine therapy prescription, and by previous HRT use
Age at first AI/tamoxifen
prescription (years)
Incident dementia
cases, N
Total person-years (1000s) Incidence rate per 1000
person-years (95% CI)
HR (95% CI)*
55–74
Tamoxifen as first endocrine therapy 61 17.29 3.53 (2.74–4.53) 1.0 (reference)
AI as first endocrine therapy 47 17.31 2.72 (2.04–3.61) 0.85 (0.58–1.25)
AI with prior tamoxifen use 22 9.19 2.39 (1.58–3.64) 0.59 (0.36–0.97)
Tamoxifen with prior AI use 2 1.20 1.67 (0.42–6.68) 0.48 (0.12–1.98)
≥ 75
Tamoxifen as first endocrine therapy 75 4.24 17.67 (14.09–22.16) 1.0 (reference)
AI as first endocrine therapy 128 6.15 20.80 (17.49–24.74) 1.19 (0.89–1.58)
AI with prior tamoxifen use 21 1.30 16.21 (10.57–24.86) 0.87 (0.53–1.41)
Tamoxifen with prior AI use 12 0.43 28.23 (16.03–49.71) 1.48 (0.80–2.72)
No previous HRT use
Tamoxifen as first endocrine therapy 109 13.54 8.05 (6.67–9.71) 1.0 (reference)
AI as first endocrine therapy 143 15.04 9.51 (8.07–11.20) 1.04 (0.81–1.34)
AI with prior tamoxifen use 33 5.88 5.61 (4.00–7.89) 0.78 (0.53–1.15)
Tamoxifen with prior AI use 9 0.92 9.80 (5.10–18.83) 0.93 (0.47–1.83)
Previous HRT use
Tamoxifen as first endocrine therapy 27 8.00 3.38 (2.32–4.92) 1.0 (reference)
AI as first endocrine therapy 32 8.42 3.80 (2.69–5.37) 1.04 (0.62–1.73)
AI with prior tamoxifen use 10 4.60 2.17 (1.17–4.04) 0.62 (0.30–1.28)
Tamoxifen with prior AI use 5 0.70 7.10 (2.96–17.06) 1.74 (0.67–4.52)
p value for interaction with age at first AI/tamoxifen prescription was 0.265; p value for interaction with HRT prescription was 0.661
AI aromatase inhibitor, HR hazard ratio, HRT hormone replacement therapy
* From Cox regression with age as timescale
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Results
Study population and baseline characteristics
We identified 14,214 postmenopausal women with a first pre-
scription for an AI or tamoxifen following a first breast cancer
diagnosis. Among these, 8018 (56.4%) women started endo-
crine treatment with an AI and 6196 (43.6%) started with
tamoxifen. Baseline characteristics of the study population
are presented in Table 1. Compared with women starting on
tamoxifen, women starting treatment with an AI were slightly
older at start of follow-up and were more likely to start therapy
in later calendar years. They were also more likely to reside in
a deprived area, be obese, and have a previous record of hy-
pertension, diabetes, CVD, cerebrovascular disease, and de-
pression, but were less likely to be current smokers or alcohol
drinkers, or to have previously received HRT. The total num-
ber of women ever prescribed an AI was 10,385 (73.1%).
Among ever AI users, the majority were prescribed an AI as
initial endocrine therapy (77.2%, n = 8018), with less than a
quarter (22.8%, n = 2367) receiving an AI as part of a sequen-
tial regimen following initial tamoxifen therapy. Median
follow-up was 2.5 years among women starting treatment on
an AI and 4.8 years among women starting on tamoxifen;
maximum follow-up times in the two groups were 12.9 years
and 13.0 years respectively. Overall, 1222 patients (8.6%) had
missing data on at least one lifestyle variable.
A total of 368 incident cases of dementia (median age
82.7 years, IQR 77.0–87.2) were identified during 57,102
person-years of follow-up. Alzheimer’s disease accounted
for over a third of cases (34.5%, n = 127; median age 79.4,
IQR 73.5–85.5) and vascular dementia for a quarter (24.5%,
n = 90; median age 82.7, IQR 77.0–87.2). There was one case
of dementia with Lewy bodies (0.3%), seven cases of mixed
dementia (1.9%), and 143 cases had unknown dementia sub-
type (38.9%; median age 82.7 years, IQR 77.0 to 87.2). The
crude incidence rate of dementia was 7.46 per 1000 AI ex-
posed person-years (95% CI 6.43–8.65) among women on an
AI as their first endocrine treatment, and 6.32 per 1000 tamox-
ifen exposed person-years (95%CI 5.34–7.47) among women
on tamoxifen as their first endocrine treatment. In unadjusted
analyses, no association was seen between AI use (vs tamox-
ifen) and dementia incidence (crude incidence rate ratio com-
paring AI vs tamoxifen as first endocrine therapy, 1.18 (95%
CI 0.94–1.45). Age-adjusted HRs for the association between
AI exposure and other explanatory variables with incident
dementia are shown in Table 2. After adjustment for age, the
point estimate for the association between AI (vs. tamoxifen)
and dementia riskmoved closer still to the null; HR 1.04 (95%
CI 0.83–1.30). The age-adjusted HR was not changed by ≥
10% by any other potential confounder or following adjust-
ment for all potential confounders (fully adjusted model, HR
1.08, 95% CI 0.84–1.38) (Table 3). Therefore, the age-
adjusted model was retained as the final Cox model. In the
sensitivity analysis restricting dementia cases to those with an
incident dementia code during follow-up (excluding 18 cases
with only a dementia medication prescription), the findings
for the risk of dementia were not materially different from
those in the main analysis; HR 1.06 (95% CI 0.82–1.37).
There was no evidence that the risk of dementia with AI
therapy (vs. tamoxifen) was modified by age at start of therapy
(p = 0.265) or previous HRT use (p = 0.661) (Table 4). Testing
of non-proportional hazards indicated there was no interaction
with attained age (< 74 years or ≥ 75 years). In secondary
analyses, there was no evidence to suggest that AI exposure
(vs. tamoxifen) was associated with a different rate of either
Alzheimer’s disease or vascular dementia; age-adjusted HRs
were 0.89 (95%CI 0.61–1.31) for Alzheimer’s and 0.94 (95%
CI 0.59–1.50) for vascular dementia.
Discussion
In this large population-based cohort studywith up to 13 years’
follow-up, we found no evidence that postmenopausal breast
cancer survivors receiving treatment with an AI had a higher
risk of incident dementia compared with those on tamoxifen.
This finding was also seen for both Alzheimer’s disease and
vascular dementia.
We are unaware of other studies that have directly com-
pared the effect of AIs and tamoxifen on the risk of dementia
among postmenopausal breast cancer patients in any setting.
Our findings are, however, in line with those from a meta-
analysis of six small cross-sectional studies by Underwood
et al., who found no differences between AIs and tamoxifen
among cognitive performance in breast cancer patients [11]. It
should be noted that our findings in relation to dementia risk
do not exclude the possibility that AIs and tamoxifen have
differential effects on specific cognitive domains as tested
among patients in cognition sub-studies of RCTs. The Breast
International Group-98 (BIG-98) RCT sub-study [16] found
better mean composite cognitive scores at trial completion
among letrozole than tamoxifen arms, yet the absence of base-
line cognitive assessment means the analysis was essentially
cross-sectional. In the Tamoxifen and Exemestane Adjuvant
Multinational (TEAM) RCT sub-study [8], AI users had sig-
nificantly better executive functioning than tamoxifen users
overall and significantly better information processing speed
among women aged > 65 years but no differences in other
cognitive domains.
Strengths of our study include the large sample from a
validated data source representative of the UK demo-
graphic, and which has a high PPV for recorded dementia
diagnoses [20, 21] and high validity and completeness of
recorded breast cancer diagnoses [22]. We observed little
confounding, yet residual confounding cannot be
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excluded. In particular, chemotherapy has been linked to
cognitive impairment in breast cancer patients [26, 27] but
could not be evaluated because this information is not
captured well in CPRD GOLD. Inability to adjust for
any potential imbalances in chemotherapy between AI
and tamoxifen-only exposed patients could have biased
the results, potentially in either direction. As information
on stage and grade of breast cancer is also not systemat-
ically recorded in the database, we were also unable to
adjust for any potential confounding effect this may have
had if this was related to both dementia incidence and the
choice of endocrine therapy. Lack of information on
oestrogen-receptor positive status of the breast cancer
meant that we were unable to identify women eligible
for, but who did not receive, endocrine therapy and com-
pare their risk of dementia with that among AI/tamoxifen
exposed groups. These comparisons may have helped as-
sess the individual causal effects of each drug. We also
decided not to include comparative data from healthy con-
trols because of the likelihood of confounding by factors
related to breast cancer risk. We were only able to inves-
tigate diagnosed dementia; therefore, undiagnosed cases
will have been missed. Any misclassification of dementia
cases is likely to have been non-differential between ex-
posure groups, which may have biased results towards the
null. As CPRD GOLD captures all prescriptions issued in
general practice, misclassification of AI and tamoxifen
exposure is likely minimal, although prescriptions issued
in secondary care may have been missed. Whether pre-
scriptions are filled and medications are taken is un-
known, yet both would be expected among women with
a condition as serious as breast cancer.
Further evaluation of the cognitive safety of adjuvant en-
docrine breast cancer therapy in other large population-based
cohorts is needed to corroborate our findings, including ex-
ploration of possible age-related and treatment duration ef-
fects, as well as potential effects of previous tamoxifen treat-
ment. It is also important to note that our findings do not rule
out the possibility that both AIs and tamoxifen are detrimental
in terms of dementia risk compared with no endocrine therapy.
Tamoxifen has oestrogen antagonist properties in some tissue
(e.g. breast) and agonist properties in others (e.g. bone) but its
action in the brain is unknown and it could potentially have an
independent causal association with dementia risk. Among
cognition RCT sub-studies and the few large observational
studies on this topic, findings have been mixed, and compar-
isons are limited by heterogeneity in the study population, the
exposure and comparison groups, and the specific cognitive
outcome(s) evaluated [8–10, 12].
Dementia is a common disease, with an estimated preva-
lence of 7% among the general population aged over 65 years
[28]; therefore, any effect of drug treatments on risk would be
of public health importance. There is a need for further work
involving separate evaluation of AIs and tamoxifen compared
with no endocrine treatment to rule out our study’s null find-
ing being a result of similar drug effects in both drug classes.
Further research into the effect AIs have on anatomy, physi-
ology, and metabolism, and on clinical events such as stroke,
would also help better understand any effects on biological
mechanisms linked to dementia risk and help build a more
comprehensive understanding in this complex field.
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